Tanaka, Tetsuhiro
Nangaku, Masaomi
Imai, Enyu
Tsubakihara, Yoshiharu
Kamai, Masatoshi
Wada, Michihito
Asada, Shinji
Akizawa, Tadao
Funding for this research was provided by:
Kyowa Hakko Kirin
Article History
Received: 6 March 2018
Accepted: 14 August 2018
First Online: 4 September 2018
Change Date: 23 January 2019
Change Type: Correction
Change Details: In the original publication of the article, two sentences in the “Results” section were published incorrectly. The corrected texts are provided below:
Compliance with ethical standards
:
: Kyowa Hakko Kirin Co., Ltd. provided funding for the DREAM-J surveillance study. Masaomi Nangaku, Enyu Imai, Yoshiharu Tsubakihara, and Tadao Akizawa are members of the scientific advisory board of the DREAM-J surveillance study. Tetsuhiro Tanaka has received lecture fees from Kyowa Hakko Kirin Co., Ltd. Masaomi Nangaku has received lecture fees from Kyowa Hakko Kirin Co., Ltd., Daiichi Sankyo Company, Limited, MSD K.K., Astellas Pharma Inc., AstraZeneca, Alexion Pharmaceuticals, Inc., Mitsubishi Tanabe Pharma Corporation, Japan Tobacco Inc., GlaxoSmithKline K.K., and Otsuka Pharmaceutical Co., Ltd.; manuscript fees from Kyowa Hakko Kirin Co., Ltd.; and scholarship/grant/research support from Kyowa Hakko Kirin Co., Ltd., Astellas Pharma Inc., Daiichi Sankyo Company, Limited, Chugai Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, and Torii Pharmaceutical Co., Ltd. Enyu Imai has received lecture fees from Kyowa Hakko Kirin Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company, Limited, Nippon Boehringer Ingelheim Co., Ltd., and Otsuka Pharmaceutical Co., Ltd., and manuscript fees from Kyowa Hakko Kirin Co., Ltd. Yoshiharu Tsubakihara has received lecture fees from Chugai Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Torii Pharmaceutical Co., Ltd., and Otsuka Pharmaceutical Co., Ltd.; scholarship/grant/research support from Bayer Yakuhin, Ltd.; and sponsorship for courses from Chugai Pharmaceutical Co., Ltd., and Baxter Limited. Tadao Akizawa is a board member/advisor/consultant for Kyowa Hakko Kirin Co., Ltd., Astellas Pharma Inc., Bayer Yakuhin, Ltd., Fuso Pharmaceutical Industries, Ltd., Japan Tobacco Inc., Ono Pharmaceutical Co., Ltd., and NIPRO; has received lecture fees from Kyowa Hakko Kirin Co., Ltd., Chugai Pharmaceutical Co., Ltd., Bayer Yakuhin, Ltd., Kissei Pharmaceutical Co., Ltd., and Torii Pharmaceutical Co., Ltd.; and has received manuscript fees from Astellas Pharma Inc. Masatoshi Kamai, Michihito Wada, and Shinji Asada are employees of Kyowa Hakko Kirin Co., Ltd.
: Informed consent and institutional review board approval were not required in the present surveillance according to GPSP. This article does not contain any studies with animals performed by any of the authors.